R. Agency has been appointed to lead the global communications strategy for Polaroid Therapeutics. Founded in 2022, Polaroid Therapeutics is developing antimicrobial therapies based on proprietary AVX technology, designed to prevent and inhibit infections in multiple indications such as acute and chronic wounds. This technology is a breakthrough solution without antimicrobial resistance which is regarded as the biggest global threat to health.

R. Agency, part of Steven Barlett’s Flight Story Group, has been briefed to lead media and stakeholder management ahead of the brand’s product launch in a year. The global brief will see the R. Agency team increase awareness through industry-focused storytelling, thought leadership and healthcare events.